Irwin Naturals Refocuses on Core Business
Company Announcements

Irwin Naturals Refocuses on Core Business

Irwin Naturals Inc (TSE:IWIN) has released an update.

Irwin Naturals Inc. has announced the closure of its ketamine clinic division to refocus on its core business of botanical supplements, a sector that has been central to the brand for over two decades. The company also revealed changes in executive positions with Mark Green replacing Sean Sand as CFO, and the board of directors seeing the departure of Rod Kight and Sheri Orlowitz, with new members Luke Lokhorst and Lyle Maxson taking their places.

For further insights into TSE:IWIN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyIrwin Naturals price target lowered to $3.00 from $4.50 at Roth MKM
TheFlyIrwin Naturals reports Q2 EPS ($1.57) vs. 0c last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App